

To: VPD Meetings [5.1.2e @ecdc.europa.eu]; [5.1.2e @cepi.net]; [5.1.2e @cepi.net]; [5.1.2e @hzjz.hr]; [5.1.2e @phe.gov.uk]; [5.1.2e @phe.gov.uk]; [5.1.2e @who.int]; [5.1.2e @who.int]; [5.1.2e @rki.de]; [5.1.2e @rki.de]; [5.1.2e @sciensano.be]; [5.1.2e @sciensano.be]; [5.1.2e @szu.cz]; [5.1.2e @szu.cz]; [5.1.2e @thl.fi]; [5.1.2e @thl.fi]; [5.1.2e @santepubliquefrance.fr]; [5.1.2e @santepubliquefrance.fr]; [5.1.2e @hse.ie]; [5.1.2e @hse.ie]; [5.1.2e @ms.etat.lu]; [5.1.2e @ms.etat.lu]; [5.1.2e @gov.mt]; [5.1.2e @gov.mt]; [5.1.2e @rivm.nl]; [5.1.2e @pzh.gov.pl]; [5.1.2e @pzh.gov.pl]; [5.1.2e @zakazny.pl]; [5.1.2e @zakazny.pl]; [5.1.2e @insa.min-saude.pt]; [5.1.2e @insa.min-saude.pt]; [5.1.2e @mscbs.es]; [5.1.2e @mscbs.es]; [5.1.2e @fhi.no]; [5.1.2e @fhi.no]; [5.1.2e @yahoo.com]; [5.1.2e @yahoo.com]; [5.1.2e @eody.gov.gr]; [5.1.2e @eody.gov.gr]; [5.1.2e @cepi.net]; [5.1.2e @cepi.net]; [5.1.2e @hzjz.hr]; [5.1.2e @hzjz.hr]; [5.1.2e @who.int]; [5.1.2e @who.int]; [5.1.2e @rki.de]; [5.1.2e @rki.de]; [5.1.2e @sciensano.be]; [5.1.2e @sciensano.be]; [5.1.2e @szu.cz]; [5.1.2e @szu.cz]; [5.1.2e @thl.fi]; [5.1.2e @thl.fi]; [5.1.2e @santepubliquefrance.fr]; [5.1.2e @santepubliquefrance.fr]; [5.1.2e @hse.ie]; [5.1.2e @hse.ie]; [5.1.2e @ms.etat.lu]; [5.1.2e @ms.etat.lu]; [5.1.2e @gov.mt]; [5.1.2e @gov.mt]; [5.1.2e @rivm.nl]; [5.1.2e @pzh.gov.pl]; [5.1.2e @pzh.gov.pl]; [5.1.2e @insa.min-saude.pt]; [5.1.2e @insa.min-saude.pt]; [5.1.2e @mscbs.es]; [5.1.2e @mscbs.es]; [5.1.2e @fhi.no]; [5.1.2e @fhi.no]; [5.1.2e @yahoo.com]; [5.1.2e @yahoo.com]; [5.1.2e @eody.gov.gr]; [5.1.2e @eody.gov.gr]

Cc: [5.1.2e @ecdc.europa.eu]; [5.1.2e @epiconcept.fr]; [5.1.2e @epiconcept.fr]; [5.1.2e @epiconcept.fr]; [5.1.2e @epiconcept.fr]; [5.1.2e @ecdc.europa.eu]; VPD VPD [5.1.2e @ecdc.europa.eu]

From: [5.1.2e]

Sent: Fri 1/22/2021 12:33:51 PM

Subject: RE: ECDC meetings on development of COVID-19 VE protocols: 26th and 29 January CET 14-16

Received: Fri 1/22/2021 12:34:42 PM

Dear colleagues,

We would really appreciate if you could send the study protocol for the vaccine effectiveness studies in the Health care workers, in order to read it before the meeting on Tuesday and envisage our possibilities of implementation in [5.1.2a]

With kind regards,

[5.1.2e]

[5.1.2e] PhD

[5.1.2e]

Instituto de Salud Carlos III
Monforte de Lemos 5, 28029 Madrid

Tel: 34 [5.1.2e]

Fax: 34 [5.1.2e]

[5.1.2e] @isciii.es

De: VPD Meetings [5.1.2e @ecdc.europa.eu]

Enviado el: martes, 19 de enero de 2021 13:31

Para: [5.1.2e @cepi.net] <[5.1.2e @cepi.net]>; [5.1.2e @hzjz.hr] <[5.1.2e @hzjz.hr]>; [5.1.2e @phe.gov.uk] <[5.1.2e @phe.gov.uk]>; [5.1.2e @who.int] <[5.1.2e @who.int]>; [5.1.2e @rki.de] <[5.1.2e @rki.de]>; [5.1.2e @sciensano.be] <[5.1.2e @sciensano.be]>; [5.1.2e @szu.cz] <[5.1.2e @szu.cz]>; [5.1.2e @thl.fi] <[5.1.2e @thl.fi]>; [5.1.2e @santepubliquefrance.fr] <[5.1.2e @santepubliquefrance.fr]>; [5.1.2e @hse.ie] <[5.1.2e @hse.ie]>; [5.1.2e @ms.etat.lu] <[5.1.2e @ms.etat.lu]>; [5.1.2e @gov.mt] <[5.1.2e @gov.mt]>; [5.1.2e @rivm.nl] <[5.1.2e @rivm.nl]>; [5.1.2e @pzh.gov.pl] <[5.1.2e @pzh.gov.pl]>; [5.1.2e @zakazny.pl] <[5.1.2e @zakazny.pl]>; [5.1.2e @insa.min-saude.pt] <[5.1.2e @insa.min-saude.pt]>; [5.1.2e @mscbs.es] <[5.1.2e @mscbs.es]>; [5.1.2e @isciii.es] <[5.1.2e @isciii.es]>; [5.1.2e @fhi.no] <[5.1.2e @fhi.no]>; [5.1.2e @yahoo.com] <[5.1.2e @yahoo.com]>; [5.1.2e @eody.gov.gr] <[5.1.2e @eody.gov.gr]>; [5.1.2e @cepi.net] <[5.1.2e @cepi.net]>; [5.1.2e @hzjz.hr] <[5.1.2e @hzjz.hr]>; [5.1.2e @who.int] <[5.1.2e @who.int]>; [5.1.2e @rki.de] <[5.1.2e @rki.de]>; [5.1.2e @sciensano.be] <[5.1.2e @sciensano.be]>; [5.1.2e @szu.cz] <[5.1.2e @szu.cz]>; [5.1.2e @thl.fi] <[5.1.2e @thl.fi]>; [5.1.2e @santepubliquefrance.fr] <[5.1.2e @santepubliquefrance.fr]>; [5.1.2e @hse.ie] <[5.1.2e @hse.ie]>; [5.1.2e @ms.etat.lu] <[5.1.2e @ms.etat.lu]>;

5.1.2e @gov.mt' <5.1.2e@gov.mt>; 5.1.2e @rivm.nl' <5.1.2e@rivm.nl>; 5.1.2e @pzh.gov.pl' <5.1.2e@pzh.gov.pl>; 5.1.2e @insa.min-saude.pt' <5.1.2e@insa.min-saude.pt>; 5.1.2e @mscbs.es' <5.1.2e@mscbs.es>; 5.1.2e @isciii.es>; 5.1.2e @fhi.no' <5.1.2e@fhi.no>; 5.1.2e @yahoo.com' <5.1.2e@yahoo.com>; 5.1.2e @eody.gov.gr' <5.1.2e@eody.gov.gr>
 CC: 5.1.2e @epiconcept.fr' <5.1.2e@epiconcept.fr>; 5.1.2e @ecdc.europa.eu>; 5.1.2e @epiconcept.fr' <5.1.2e@epiconcept.fr>; 5.1.2e @ecdc.europa.eu>; VPD VPD <5.1.2e@ecdc.europa.eu>; VPD Meetings <5.1.2e@ecdc.europa.eu>

Asunto: ECDC meetings on development of COVID-19 VE protocols: 26th and 29 January CET 14-16

Dear colleague,

ECDC is planning to implement vaccine effectiveness studies in the EU/EEA and will hold a consultation to discuss study designs and methods of studies against severe disease through a hospital setting and in a selected target group (health care workers). The aim is to inform the creation of EU/EEA study protocols. In order to implement the studies, ECDC is working closely with Epiconcept who has been awarded the project.

We would like to invite you to contribute to the Expert meeting on the development of EU/EEA study protocols for COVID-19 vaccine effectiveness studies.

The dates of the meeting are the following:

- **Tuesday 26 January 2021: 14.00-16.00hrs (CET) – Health care workers study**
- **Friday 29 January 2021: 14.00-16.00hrs (CET) – Hospital study (severe disease)**

Please let us know if you are able to participate to the meeting by:

Responding to this email and filling in the ECDC annual Declaration of Interest by **Thursday 21st** (it is possible you have filled in this document before, if so there is no need to fill it in again), see instructions attached.

If you are unable to join the call and would like to propose another colleague, please let us know and we will evaluate the possibility for him/her to join the meeting.

Details on the connection via zoom will be sent by Epiconcept.

Attached:

- Agenda
- Scope and purpose
- Instructions on the annual Declaration of Interest
- I-MOVE COVID-19 study protocol (for information only)

We thank you in advance and look forward to your participation,
 With kind regards

5.1.2e [redacted] 5.1.2e [redacted] and 5.1.2e [redacted]



European Centre for Disease Prevention and Control (ECDC)

Gustav III:s boulevard 40, 169 73 Solna, Sweden

5.1.2e [redacted]

www.ecdc.europa.eu

Follow ECDC on:



Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.

***** AVISO LEGAL ***** Este mensaje electrónico está dirigido exclusivamente a sus destinatarios, pudiendo contener documentos anexos de carácter privado y confidencial. Si por error ha recibido este mensaje y no se encuentra entre los destinatarios, por favor no use, informe, distribuya, imprima o copie su contenido por ningún medio. Le rogamos lo comunique al remitente y borre completamente el mensaje y sus anexos. El Instituto de Salud Carlos III no asume ningún tipo de responsabilidad legal por el contenido de este mensaje cuando no responda a las funciones atribuidas al remitente del mismo por la normativa vigente.